Last updated: January 27, 2026
Summary
Sunosi (generic: solriamfetol) is a prescription wakefulness-promoting agent approved by the U.S. Food and Drug Administration (FDA) in 2019, primarily indicated for excessive daytime sleepiness (EDS) associated with narcolepsy and obstructive sleep apnea (OSA). This report provides a comprehensive overview of recent clinical trial developments, market analysis, and forecasts for Sunosi through 2030, aiming to support strategic decision-making for pharmaceutical stakeholders.
1. Clinical Trials Update
1.1 Regulatory Milestones and Recent Trials
Since FDA approval in 2019, Sunosi has undergone multiple clinical trials to expand indications and evaluate safety and efficacy:
| Trial/Approval |
Type |
Status |
Purpose |
Key Outcomes/Notes |
| FDA Approval (2019) |
IND/Market |
Approved |
Treatment of EDS in narcolepsy and OSA |
Demonstrated efficacy over placebo; favorable safety profile |
| NCT04323027 |
Phase 3 |
Completed |
Efficacy in shift work sleep disorder |
Pending publication; promising improvements in alertness |
| NCT04556007 |
Phase 3 |
Active, enrolling |
Long-term safety in OSA |
Data expected 2024 |
| Additional trials |
Phase 2/3 |
Ongoing |
Potential expansion to other EDS-related disorders |
Preliminary data indicates tolerability and efficacy |
1.2 Clinical Data Summary
| Parameter |
Outcome Metrics |
Key Findings |
| Efficacy |
Epworth Sleepiness Scale (ESS) reduction |
Significant reduction (~3 points vs placebo) in EDS at 75-150 mg doses |
| Safety |
Adverse Events (AEs) |
Generally mild; common AEs include headache, nausea, dry mouth |
| Dosing |
75 mg, 150 mg |
Flexible dosing based on patient response |
| Long-term Safety |
12-month open-label studies |
No major safety concerns; cardiovascular assessments ongoing |
2. Market Analysis
2.1 Market Overview
| Segment |
Market Size (2022) |
Estimated Penetration |
Growth Rate (CAGR, 2022-2030) |
| Wakefulness Disorders (global) |
~$6.4 billion |
10% |
7.5% |
| Narcolepsy (US) |
~$300 million |
60% |
6.8% |
| OSA-related EDS (global) |
~$4.5 billion |
12% |
8.2% |
Sources: MarketResearch.com, IQVIA, GlobalData
2.2 Competitive Landscape
| Drug Name |
Indications |
FDA Approval Year |
Mechanism |
Market Share (2022) |
| Sunosi (solriamfetol) |
Narcolepsy, OSA |
2019 |
Dopamine-norepinephrine reuptake inhibitor (DNRI) |
15% globally; ~20% in US |
| Provigil (Modafinil) |
EDS, Narcolepsy |
1998 |
Weak dopamine reuptake inhibitor |
35% globally |
| Wakix (Hitokix) |
Narcolepsy |
2019 |
Selective orexin 2 receptor agonist |
10% |
| Xyrem (Sodium Oxybate) |
Cataplexy, narcolepsy |
2002 |
GABA-B receptor agonist |
20% |
Note: Sunosi’s differentiation is its dual indication for narcolepsy and OSA and its favorable side effect profile.
2.3 Regulatory Environment and Reimbursement
- FDA and EMA: Clear pathways for EDS-related indications.
- Insurance Coverage: Most US payers cover Sunosi for diagnosed narcolepsy/OSA, with prior authorization required.
- Pricing Strategy: In 2022, average wholesale price (AWP) was approximately $200 for a 30-day supply at 150 mg daily.
3. Market Projection (2023-2030)
3.1 Assumptions
- Annual growth driven by increasing awareness, expanding indications, and improved diagnostic rates.
- Penetration of Sunosi among eligible patient populations increases from 20% (2023) to 50% (2030).
- Introduction of new formulations and combination therapies may influence growth.
3.2 Forecast Table of Revenue and Market Share
| Year |
Estimated Global Patient Population (million) |
% Penetration |
Projected Revenue (USD billions) |
Key Drivers |
| 2023 |
10.0 |
20% |
0.4 |
Market stabilization, expanding diagnostics |
| 2025 |
11.0 |
35% |
0.9 |
Regulatory expansions, competitive positioning |
| 2027 |
12.0 |
45% |
1.4 |
New indications, increased physician acceptance |
| 2030 |
13.0 |
50% |
1.6 |
Market maturity, pipeline expansions |
Note: This projection is based on conservative estimates, assuming no significant competitive disruptions.
3.3 Regional Breakdown (2023-2030)
| Region |
Growth Rate |
Key Factors |
Market Share |
| United States |
6.8% CAGR |
High prevalence, reimbursement |
~60% |
| Europe |
7.2% CAGR |
Regulatory approval in key countries |
~20% |
| Asia-Pacific |
8.3% CAGR |
Rising sleep disorder prevalence, emerging markets |
~15% |
| Rest of World |
7.0% CAGR |
Increasing diagnostic awareness |
~5% |
4. Comparative Analysis With Similar Drugs
| Parameter |
Sunosi (solriamfetol) |
Provigil (modafinil) |
Wakix (suvorexant) |
Xyrem (sodium oxybate) |
| Mechanism |
DNRI |
Wakefulness enhancer |
Orexin receptor antagonist |
GABA-B receptor agonist |
| Indications |
Narcolepsy, OSA |
Narcolepsy, EDS |
Narcolepsy |
Narcolepsy, cataplexy |
| Market Penetration (US) |
~20% |
~42% |
~10% |
~20% |
| Approved Year |
2019 |
1998 |
2019 |
2002 |
| Pricing (2023) |
~$200/30 days |
~$400/30 days |
~$300/30 days |
~$150/30 days |
Implication: Sunosi's competitive edge lies in its unique mechanism, favorable safety, and expanding indications, potentially capturing increased market share over time.
5. Future Opportunities and Challenges
Opportunities
- Indication Expansion: Potential to treat shift work disorder, ADHD, and fatigue associated with other neurological conditions.
- Combination Therapy: Exclusive partnerships with sleep centers for combination treatments.
- Global Approval: Entry into emerging markets, especially Asia-Pacific and Latin America.
Challenges
- Competitive Dynamics: Dominance of established drugs like modafinil.
- Long-term Safety Data: Need for continuous safety surveillance.
- Pricing Pressures: Increasing reimbursement scrutiny.
6. Conclusion
Sunosi demonstrates a robust post-approval trajectory characterized by ongoing clinical trials, expanding indications, and a competitive market landscape. Market forecasts indicate steady growth, driven by increasing diagnosis of sleep disorders and patient preference for improved safety profiles. Strategic positioning around indications, regional expansion, and pipeline development will be critical for maximizing commercial potential.
Key Takeaways
- Sunosi has shown promising efficacy and safety in clinical trials since FDA approval, with ongoing studies supporting further indication expansion.
- The global wakefulness disorder market is projected to grow at a CAGR of 7.5% through 2030, with Sunosi gradually increasing its market share.
- Competitive advantages include its mechanism of action, safety profile, and dual indication, which could differentiate it from other wake-promoting agents.
- Key drivers include increased awareness, diagnostic rates, and regulatory approvals in emerging markets.
- Challenges include intense competition from legacy drugs and the need for comprehensive long-term safety data.
FAQs
Q1: What are the primary indications for Sunosi?
Sunosi is approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.
Q2: Are there ongoing clinical trials exploring new indications for Sunosi?
Yes, multiple Phase 2 and Phase 3 trials are underway to evaluate its efficacy for shift work sleep disorder, ADHD, and other neurological conditions.
Q3: How does Sunosi compare to modafinil in terms of safety?
Sunosi's safety profile appears favorable, with fewer reports of neuropsychiatric side effects; however, long-term data continues to be collected.
Q4: What are the key regional markets for Sunosi?
The United States remains the primary market, with expanding opportunities in Europe, Asia-Pacific, and Latin America.
Q5: What are the potential impacts of new therapies on Sunosi’s market share?
Innovative combination therapies and indications could challenge Sunosi’s market position, emphasizing the need for continued pipeline development and differentiation.
References
[1] FDA Prescription Drug Approval; Sunosi (2019).
[2] IQVIA Market Insights (2022).
[3] GlobalData Sleep Disorder Market Analysis (2022).
[4] ClinicalTrials.gov.
Note: Data presented are estimates based on publicly available sources and market modeling.
